Radiosynthesis of N - 11 C-meisoindigotin as a novel PET agent for imaging of cyclin-dependent kinases and GSK-3β

Meisoindigotin has been demonstrated as a new type of cancer chemotherapeutic agent. N-11C-meisoindigotin was synthesized by N-11C-methylation of the isoindigotin precursor with 11C-labelled methyl triflate. The decay corrected radiochemical yields were 15–25%, and the specific radioactivity was 1.0–1.2Ci/μmol at the end of synthesis. The cellular uptake of [N-11C]-meisoindigotin was evaluated in four different lung cancer cell lines. Our results showed that the A549, GLC-82, 95D cell lines exhibited higher uptake than 95C cell line after incubation for 60min. N-11C-meisoindigotin was a promising candidate for further development as a novel PET radiotracer for imaging of cyclin-dependent kinases (CDKs) and GSK-3β.